68Ga-DOTATATE PET/CT in Neuroendocrine Tumor
- Registration Number
- NCT04041882
- Lead Sponsor
- Peking Union Medical College Hospital
- Brief Summary
Somatostatin receptor(SSTR) was expressed in neuroendocrine tumor cells and SSTR-targeting molecular imaging(68Ga-DOTATATE PET/CT) could be a promising technique to evaluate the primary tumor and metastatic lesions of neuroendocrine tumors with higher accuracy. This prospective study is going to investigate whether radiolabeled somatostatin analogs 68Ga-DOTATATE PET/CT may be valuable for diagnosis, risk stratification, and prognostic evaluation of neuroendocrine tumors and compared it with 18F-FDG PET/CT.
- Detailed Description
Neuroendocrine tumor(NET)can be derived from endocrine glands, endocrine tissues and endocrine cells from any parts of body. Due to its occult onset and heterogeneity, it is hard to be detected by conventional imaging like CT and it is often at late stage when diagnosed. New imaging modality such as 18F-FDG PET/CT have been well-accepted as a practical way to evaluate the aggressive of tumor. 18F-FDG PET/CT has been used to improve the efficacy in assessing the extent and severity of NET, but the diagnostic accuracy of 18F-FDG PET/CT decreased in low proliferation tumor cells and inflammation. Recent studies showed somatostatin receptor (SSTR) was expressed in NET cells and SSTR-targeting molecular imaging-68Ga-DOTATATE PET/CT could be a promising technique to evaluate the extent of NET with higher accuracy. Especially in some well differentiated tumor, 18F-FDG PET/CT can be negative, while 68Ga-DOTATATE PET/CT can be positive. However, the results can be varied in these two imaging modalities and characterized this disease at multiple levels such as clinical presentation, biologic characteristics, treatment response, and clinical outcome.This prospective study is going to investigate whether 68Ga-DOTATATE PET/CT may be superior to 18F-FDG PET/CT for diagnosis, risk stratification, and prognostic evaluation of NET.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 100
- suspected or confirmed untreated NET patients previously performed 18F-FDG PET/CT signed written consent.
- pregnancy breastfeeding known allergy against TATE any medical condition that in the opinion of the investigator, may significantly interfere with study compliance.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 68Ga-DOTATATE PET/CT 68Ga-DOTATATE Inject 68Ga-DOTATATE and then perform PET/CT scan
- Primary Outcome Measures
Name Time Method SUVmax through study completion, an average of 3 years SUVmax of focal lesions are measured on 68Ga-DOTATATE PET/CT. The SUVmax higher than that of the normal liver tissue is defined as positive.
Diagnostic value through study completion, an average of 3 years Diagnostic value of 68Ga-DOTATE PET/CT for NET in comparison with 18F-FDG PET/CT
- Secondary Outcome Measures
Name Time Method Overall Survival(OS) 1 year and 5 years after been diagnosed Analysis of OS for patients receiving 68Ga-DOTATATE PET/CT
Risk stratification through study completion, an average of 3 years Analysis of risk factors and OS/PFS
Diagnostic value in different grades/types of NET through study completion, an average of 3 years Diagnostic value of 68Ga-DOTATATE PET/CT in ectopic ACTH-secreting tumor, insulinoma, glucagonoma and so on.
SSTR expression/Ki67 and SUV through study completion, an average of 3 years Correlation between SSTR expression/Ki 67 and SUV in PET
Progressive free survival(PFS) 1 year and 5 years after been diagnosed Analysis of PFS for patients receiving 68Ga-DOTATATE PET/CT
Trial Locations
- Locations (1)
Department of Nuclear Medicine, Peking Union Medical College Hopital, Chinese Academy of Medical Science
🇨🇳Beijing, China